Evidence-based Evaluation of Irinotecan Combined with Platinum in the Treatment of Extensive Small Cell Lung Cancer

OBJECTIVE To systematically evaluate the rationality of irinotecan combined with platinum in the treatment of extensive small cell lung cancer(SCLC). METHODS Searched the latest edition of the drug instructions at home and abroad, and collected all indications of irinotecan. PubMed, Cochrane Library, EMbase, Epistemonikos, CBM, CNKI and Wanfang database were searched from database foundation to November 2018. Collected the relevant guidelines and systematic reviews of irinotecan in the treatment of extensive SCLC, and to systematically evaluate the efficacy and safety of irinotecan in the treatment of extensive SCLC. RESULTS The FDA manual mentions that irinotecan was used for extensive SCLC, but the NMPA manual did not mention. There were four guidelines recommending irinotecan combined with platinum in the treatment of extensive SCLC. Five systematic reviewed analyzed platinum combined with irinotecan or etoposide. It was generally believed that platinum combined with irinotecan could be used as a first-line treatment for extensive SCLC, but the occurrence of adverse reactions should be vigilant. CONCLUSION At present, there is sufficient evidence about platinum combined with irinotecan in the treatment of extensive SCLC, which can be recommended as a treatment for extensive SCLC.